Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><keyword id="12496770" type="General" weightage="20" keywordseo="tarsons-products-ipo" source="Orion">Tarsons Products IPO</keyword> is all set to list in stock exchanges tomorrow, November 26.</li><li>Investors have shown good interest in the IPO as it has been subscribed 77.49 times.</li><li>The grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier.</li></ul>Indian labware company Tarsons Products is all set to list its initial public offering (IPO) on stock exchanges tomorrow, November 26. The IPO has shown a good response from investors as it has been subscribed 77.49 times. While the company was looking to raise ₹1,024 crore through the IPO, it received bids for ₹55,625 crore. Investors have bid for 84 crore stocks out of 1.08 stock available for bids. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscription status </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Qualified Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">115.77 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Non-Institutional Investors </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">184.58 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Retail </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10.56 times </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Overall </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">77.49 times </td></tr></tbody></table> However, the grey market premium of the Indian labware company has come down to ₹170 from ₹200 earlier. The IPO consisted of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. “COVID has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR [compound annual growth rate] given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/how-to-check-go-fashions-ipo-allotment-status/articleshow/87891055.cms">Go Fashion IPO’s allotment status would be announced today, GMP at ₹425</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-coal-india-and-other-top-stocks-to-watch-out-for-on-november-25/slidelist/87901109.cms">Reliance Industries, Coal India and other top stocks to watch out for on November 25</a>

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

<ul><li><keyword id="12447226" type="General" weightage="20" keywordseo="tarsons" source="Orion">Tarsons</keyword> Products has received bids for 3.88 crore equity shares versus the 1.08 crore shares up for sale.</li><li>The company intends to raise ₹1,023 crore through its public issue, which includes ₹150 crore as issue of new shares.</li><li>The company will use their capital to repay its debts and spend on the manufacturing facility at Panchla in West Bengal.</li></ul>The initial public offering (IPO) of Tarsons Products continued to witness good demand from investors across the board on the second day of its public issue. The company would be listed on the <a href="https://www.businessinsider.in/stock-market/news/tarson-products-ipo-opens-today-and-closes-on-november-17/articleshow/87709719.cms">stock exchange on November 25</a>. The grey market premium of Tarsons Products shares is <a href="https://www.livemint.com/market/ipo/tarsons-products-ipo-what-gmp-signals-on-second-day-of-subscription-11637035990127.html">reportedly</a> at ₹180. Tarsons Products — which is a labware supplier to the life sciences sector— has received bids for 3.88 crore equity shares versus the 1.08 crore shares that were up for sale. The retail portion has been oversubscribed by 4.74 times and the portion reserved for non-institutional investors has been subscribed 3.98 times. Qualified institutional buyers — which includes banks, mutual funds and others — have subscribed to the IPO 1.30 times. The issue has been subscribed by 3.6 times. Tarsons Products’ public issue will close today, November 17. Interest investors can place their bidding, within a range of ₹645-662 apiece. The lot size has been set at 22 shares,which means that the investors would have to spend at least ₹14,190 to subscribe to the shares. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. It manufactures a range of quality labware products that helps advance scientific discovery and improve healthcare. The company intends to raise ₹1,023 crore through its public issue, which comprises ₹ 150 crore as fresh issue. The remaining ₹873 crore will be raised through offer for sale (OfS) and will go to the investors selling their shares in the IPO. The company will use their capital to repay its debts and spend on the manufacturing facility at Panchla in West Bengal. SEE ALSO <a href="https://www.businessinsider.in/business/startups/news/former-myntra-ceo-started-mensa-brand-in-may-and-its-already-worth-a-billion-dollars-with/articleshow/87735832.cms" data-type="tilCustomLink" style="">Former Myntra CEO started Mensa Brand in May ⁠and it’s already worth a billion dollars</a> <a href="https://www.businessinsider.in/cryptocurrency/news/cryptocurrencies-tumble-as-china-continues-its-crackdown-against-mining/articleshow/87738496.cms" data-type="tilCustomLink" style="">Cryptocurrencies tumble as China continues its crackdown against mining</a> <a href="https://www.businessinsider.in/stock-market/news/reliance-industries-makes-for-nearly-third-of-niftys-fall-today-tata-motors-and-maruti-beat-the-trend/articleshow/87736157.cms" data-type="tilCustomLink" style="">Reliance Industries makes for nearly a third of Nifty’s fall today ⁠— Tata Motors and Maruti beat the trend</a>

Tarsons Products IPO — today is the last day to subscribe, GMP at ₹180

<ul><li>Tarsons Products’ ₹1,000 crore IPO had opened on November 15 and will close on November 17.</li><li>Nearly one in every ten lab equipment sold in India is from Tarsons.</li><li>The <keyword id="938640" type="General" weightage="20" keywordseo="grey-market-premium" source="Orion">grey market premium</keyword> of the Indian labware company surged to ₹230 from ₹200.</li><li>Check out the latest news and updates on Business Insider.</li></ul>Today is the second day to subscribe to the Indian labware company Tarsons Products initial public offering (IPO), which will close on November 17. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. The ₹1,024 crore IPO consists of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. The company said it will repay debt with the money from the IPO and build its sixth manufacturing facility at Panchla in West Bengal . Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Broking firms </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Recommendation </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ventura Securities </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Nirmal Bang </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Angel One </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Investmentz </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Swastika </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Ashika Research </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe for long term </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Choice Broking </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Subscribe with caution </td></tr></tbody></table> Analysts are betting big on the healthcare sector even post covid and expect the labware products company to continue growing. The grey market premium of the Indian labware company surged to ₹230 from ₹200 earlier. “Covid has turned out to be a boon for the companies in the healthcare space as worldwide governments have started allocating more funds and people in general have become more conscious towards the healthcare benefits. We expect the firm to grow faster than current CAGR given the laboratory instrument industry is growing at 20%,” said analysts at Nirmal Bang. <div type="image" title="tarsons product" height="900" width="1200" msid="87730870" hostid="261"></div> Besides, the fact that the company cut down its debt by half in two years has impressed analysts. The company total borrowings came down to ₹33 crore in FY21 from ₹64 crore in FY19. Further, the company said it will utilise ₹78 crore from the IPO proceeds to repay/prepayment debt. “The margins of the company have grown significantly on the back of declining debt. The company aims to be debt free post the IPO and is planning for CAPEX (capital expenditure) which will further increase the revenues,” said analysts at Swastika. However, analysts at Choice Broking believe that the sharp spike in growth last year may be a one-off event triggered by the pandemic and the company may find it difficult to maintain the same pace in the future. “There is a respectable import market for the company to capture and also a huge export opportunity arising from the “China plus one” strategy, in case the globe adopts this strategy in the post-Covid period. Thus considering the future growth outlook and the demanded premium valuation, we assign a “Subscribe with Caution” rating for the issue,” the report said. Simply put, the threat of international competition and rising imports is just as valid as the hope of a boom in business for Tarsons. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/policybazzar-and-sigachi-share-price-jump-in-early-trading/articleshow/87730171.cms">Policybazaar gets a boost after an American fund laps up 3.4 million shares and Sigachi hits upper circuit on the morning after listing</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/personal-finance/news/now-you-can-invest-in-global-blockchain-companies-through-this-mutual-fund-heres-how-to-do-it/articleshow/87724967.cms">Now you can invest in global blockchain companies through this mutual fund ⁠— here's how to do it</a>

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

<ul><li>Tarsons Products announced its share allotment status on Tuesday.</li><li>The grey market premium of the Indian labware company Tarsons Products is ₹160.</li><li>The IPO of the company was subscribed 77.49 times on the last day of bidding.</li></ul>The allotment status of Indian labware company Tarsons Products was announced on Tuesday and by now the investors, who unfortunately did not get the shares, should start getting their refunds. If you have not checked whether you received the initial public offering (IPO) allotment or not, <a href="https://www.businessinsider.in/stock-market/news/tarsons-products-ipo-heres-how-to-check-your-allotment-status/articleshow/87857321.cms">click here </a>and follow the procedure. All the investors who got the allotment will receive the shares in their demat account on the date of listing, which in this case is November 26. Usually every applicant gets a message on their registered phone number, highlighting whether the funds are blocked or unblocked. Blocked funds indicate that the shares have been transferred to the investor, whereas the unblocked fund means that the cash has been transferred back to the investor’s bank account. Investors receive a validity period while making the payments for the shares. The IPO amount is usually refunded one day later the IPO allotment or before the end of the validity period. <div type="image" title="If you missed Tarson Products’ IPO allotment, here’s what you should know" msid="87870784" hostid="261"></div> Tarsons Products opened its IPO on November 15 to November 17, at a price band of ₹635-₹662 per share. The IPO received subscriptions for 77.49 times the number of shares offered in the three days of IPO bidding process. The grey market premium of the company’s shares show a premium of ₹160 on November 23. The company has raised over ₹1,024 crore through the IPO of a fresh issue of equity shares worth ₹150 crore and an offer for sale (OFS) of 1.32 crore equity shares that will be sold by promoters and an investor. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. SEE ALSO <a href="https://www.businessinsider.in/business/telecom/news/jio-is-slowing-down-in-the-race-to-500-million-subscribers/articleshow/87862415.cms">Jio is slowing down in the race to 500 million subscribers – a goal set by none other than Mukesh Ambani</a> <a href="https://www.businessinsider.in/business/startups/news/nobroker-is-the-38th-indian-startup-to-be-valued-over-a-1-billion-in-2021/articleshow/87867289.cms">NoBroker is the 38th Indian startup to be valued over a billion dollars this year</a> <a href="https://www.businessinsider.in/business/telecom/news/vodafone-idea-hikes-tariffs-by-up-to-500-for-its-popular-plans/articleshow/87864183.cms">Vodafone Idea hikes tariffs by up to ₹500 for its popular plans</a>

If you missed Tarson Products’ IPO allotment, here’s what you should know

<ul><li>Shares of Tarsons Products listed at ₹700 while the price band was fixed at ₹635-662 per share.</li><li>The IPO was a hit among investors as it has been subscribed just 77.49 times on the last day of the bidding.</li><li>The market capitalisation of the company stood at ₹3,724 crore.</li></ul>Shares of Indian labware company Tarsons Products made a decent listing on the National Stock Exchange (NSE) and BSE despite weak market trends. The stock listed at ₹700, higher 5.74% on the issue price band of ₹635-662 apiece. Investors were expecting a positive listing despite weak market trends as the fundamentals of the company like becoming debt-free, having strong cash flow looked attractive. “The company has a strong cash flow and it is likely to become debt-free post-IPO [initial public offering] however the valuations look expensive therefore aggressive investors with a long-term view can hold this stock while those who were playing for listing gain should book profit because we are expecting some listing gain of around 20-25% based on subscription figure and grey market trend current GMP 180 (+27%),” said Aayush Agrawal, senior research analyst, merchant banking at Swastika Investmart. Post listing, the market capitalisation of the company stood at ₹3,724 crore, according to BSE data. The shares of Tarsons Products were trading at ₹722, higher by 9% at 10.00 a.m., on November 26. The grey market had indicated a strong listing too as unlisted shares of Tarsons Products were commanding a marginal premium of ₹180 per share. The IPO, which was open between November 15 and November 17, received strong response from investors. It was subscribed 77.49 times on the last day of the bidding. Tarsons Products is engaged in designing, developing, manufacturing and supplying a diverse range of quality labware products used in laboratories across research organisations, academic institutes, pharmaceutical firms, diagnostics companies and hospitals. Some of the company’s clients include Dr Reddy's Laboratories, Metropolis Healthcare, Dr. Lal Path Labs. Tarsons sells nearly one in every ten labware products sold in India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/ratan-tata-backed-upstox-is-now-valued-more-than-its-rivals-zerodha-and-groww/articleshow/87922976.cms">Ratan Tata-backed Upstox is now valued more than its rivals Zerodha and Groww</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/reliance-industries-tarsons-products-asian-paints-and-other-hot-stocks-on-november-26/slidelist/87921730.cms">Reliance Industries, Tarsons Products, Asian Paints and other hot stocks on November 26</a>

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

<ul><li>Cigarette-to-FMCG conglomerate <keyword id="6357073" type="General" weightage="20" keywordseo="itc" source="Orion">ITC</keyword> has initiated clinical trials of nasal sprays for COVID-19 prevention.</li><li>The product has been developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru.</li><li>The company plans to market the nasal spray under the Savlon brand after regulatory approvals.</li></ul>Diversified entity ITC on Thursday confirmed that it is developing a nasal spray for COVID-19 prevention for which it has initiated clinical trials. Developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru, the company plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals, according to sources. When contacted for comments, a spokesperson of ITC said, "We are unable to share more details at the current moment as the clinical trials are underway." The spokesperson declined to comment on a detailed query on where is the clinical trial being done, from where the commercial production would be done when approved and under what brand the nasal spray would be marketed. However, sources said the company had received approvals from ethics committees and is registered with Clinical Trial Registry-India (CTRI) for clinical trials of the nasal spray which is designed to arrest the virus at the entry point in the nasal cavity itself. They further said the product has the potential to be effective and safe in preventing infection and transmission of COVID-19 along with the existing measures of hygiene recommended by health authorities. ITC's LSTC has been at the core of the company's drive for science led product innovation to support and build its wide range of product portfolio. The company's R&amp;D teams were instrumental in developing a range of innovative health and hygiene offerings that were commercially made available under the Savlon brand, during the pandemic. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/investment/news/heres-a-quick-look-at-how-the-evolution-of-cryptocurrencies-has-played-out-in-india/slidelist/87902549.cms">India’s crypto regulations have been caught in limbo — here’s how the past decade has played out</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/tarsons-products-ipo-is-listing-on-november-26-gmp-staggers-around-170/articleshow/87902416.cms">Tarsons Products IPO listing tomorrow; GMP staggers around ₹170</a>

ITC starts clinical trials of its COVID-19 nasal spray, say sources

Two doses of <keyword id="9485939" type="General" weightage="20" keywordseo="Covaxin" source="Orion">Covaxin</keyword> are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in <keyword id="456544" type="General" weightage="20" keywordseo="The-Lancet" source="Orion">The Lancet</keyword> Infectious Diseases journal. The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns. The latest study assessed 2,714 hospital workers at the <keyword id="6365231" type="General" weightage="20" keywordseo="All-India-Institute-of-Medical-Sciences" source="Orion">All India Institute of Medical Sciences</keyword> (AIIMS) in Delhi, from April 15 May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases. Covaxin, developed by Hyderabad-based <keyword id="149108" type="General" weightage="20" keywordseo="Bharat-Biotech" source="Orion">Bharat Biotech</keyword> in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India's second COVID-19 surge and in healthcare workers who were primarily offered Covaxin. "Our study offers a more complete picture of how BBV152 (Covaxin) performs in the field and should be considered in the context of COVID-19 surge conditions in India, combined with the possible immune evasive potential of the Delta variant," said Manish Soneja, Additional Professor of Medicine at AIIMS New Delhi. "Our findings add to the growing body of evidence that rapid vaccine rollout programmes remain the most promising path to pandemic control while public health policies must continue to include additional protective measures, such as mask-wearing and social distancing," Soneja said in a statement. The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees. Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection. Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2, the virus that causes COVID-19, and 1,097 tested negative. Positive cases were matched to negative RT-PCR tests (controls). The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates. The study found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent. The effectiveness of two vaccine doses remained stable over the seven-week follow-up period, the researchers said. The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said. "Findings from the study confirm previous research indicating that two doses of BBV152 are required to achieve maximum protection and that all vaccine roll-out plans must follow the recommended dosing schedule," said Parul Kodan, Assistant Professor of Medicine at AIIMS New Delhi. "More research is needed to better understand how these findings translate to BBV152's effectiveness against delta and other variants of concern, especially related to severe COVID-19 infection, hospitalisation, and deaths," Kodan said. The authors acknowledge that the vaccine <keyword id="12595121" type="General" weightage="20" keywordseo="effectiveness-of-Covaxin" source="Orion">effectiveness of Covaxin</keyword> estimated in this study is lower than the efficacy reported by the recently published phase 3 trial. They noted that several factors may be responsible for the lower vaccine effectiveness in the latest study. The researchers said this study population only included hospital employees who may have a higher risk of exposure to COVID-19 infection than the general population. The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said. Prevalence of circulating variants of concern, especially Delta, may have also contributed to the vaccine's lower effectiveness, according to the researchers. The authors acknowledge several limitations to their study. The study does not estimate the vaccine effectiveness against hospitalisation, severe disease, and death, which require further assessment, they noted. Also, the study was not designed to estimate vaccine effectiveness for different time intervals after vaccination or to determine if vaccine effectiveness changed over time, the researchers added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/url-go-fashion-ipo-allotment-tomorrow-and-gmp-is-falling-every-day/articleshow/87876496.cms">Go Fashion IPO allotment tomorrow; GMP on a downward trend</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/if-you-missed-tarson-products-ipo-allotment-heres-what-you-should-know/articleshow/87870822.cms">If you missed Tarson Products’ IPO allotment, here’s what you should know</a>

You Searched For "tarsons ipo gmp" and got 7 results

Tarsons Products IPO listing tomorrow; GMP staggers around ₹170

Bhakti Makwana

Tarsons Products IPO — today is the last day to subscribe, GMP at ₹180

Kritti Bhalla

The IPO from Tarsons, a Bengal-based supplier for Dr Lal Path Labs and Dr Reddy’s, gets a unanimous ‘subscribe’ call from the street

Bhakti Makwana

If you missed Tarson Products’ IPO allotment, here’s what you should know

Kritti Bhalla

Tarsons Products makes a decent stock market debut amid weak market trend; lists at 6% premium

Bhakti Makwana

ITC starts clinical trials of its COVID-19 nasal spray, say sources

PTI

Covaxin shows 50% effectiveness against symptomatic COVID-19 in real-world assessment, says Lancet study

PTI

Popular Keywords

Buying Guides